VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock.

Several other analysts have also recently weighed in on the company. Benchmark restated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd. D. Boral Capital reiterated a “buy” rating and set a $5.00 target price on shares of VolitionRx in a research report on Wednesday, January 8th.

VolitionRx Stock Performance

Shares of VNRX opened at $0.66 on Wednesday. The stock has a market capitalization of $61.16 million, a price-to-earnings ratio of -1.83 and a beta of 1.20. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23. The stock has a fifty day moving average of $0.65 and a 200-day moving average of $0.66.

Insider Transactions at VolitionRx

In other news, CEO Cameron John Reynolds bought 139,811 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was acquired at an average price of $0.57 per share, with a total value of $79,692.27. Following the completion of the purchase, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Guy Archibald Innes purchased 174,764 shares of the business’s stock in a transaction on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the transaction, the director now directly owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. The trade was a 39.51 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 358,266 shares of company stock worth $204,212 over the last ninety days. 12.80% of the stock is owned by insiders.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC lifted its stake in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the Securities & Exchange Commission. 8.09% of the stock is owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.